Shares of Durect Corporation plunged more than 31 percent after the company announced the Phase IIa plaque psoriasis treatment sulfated oxysterol failed to distinguish itself against placebo.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-01-03 11:42:512020-01-03 11:42:51Durect Drug Fails to Shine in Plaque Psoriasis Study
